Improved Treatment for Cervical Cancer — Concurrent Chemotherapy and Radiotherapy
- 15 April 1999
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (15) , 1198-1200
- https://doi.org/10.1056/nejm199904153401509
Abstract
Despite screening programs, approximately 14,000 cases of invasive cervical cancer are diagnosed annually in the United States. In approximately half these cases, locally advanced disease is present at the time of diagnosis. In developing countries, the disease is usually advanced by the time of diagnosis, the prevalence is much higher, and cervical cancer is the principal cause of death due to cancer in women.Pelvic radiation has been the standard, definitive therapy for advanced disease. With this treatment, the overall five-year survival rate is approximately 65 percent, but it ranges from 15 to 80 percent, depending on the extent of . . .Keywords
This publication has 5 references indexed in Scilit:
- Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical CarcinomaNew England Journal of Medicine, 1999
- Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical CancerNew England Journal of Medicine, 1999
- Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical CancerNew England Journal of Medicine, 1999
- A Randomized Trial of Standard versus Partially Hyperfractionated Radiation with or without Concurrent 5-Fluorouracil in Locally Advanced Cervical CancerGynecologic Oncology, 1998
- Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20Published by American Medical Association (AMA) ,1995